DR. KAILASH S SENIOR RESIDENT ANTIDEPRESSANTS - PHARMACODYNAMICS
Preview:
Citation preview
- Slide 1
- DR. KAILASH S SENIOR RESIDENT ANTIDEPRESSANTS -
PHARMACODYNAMICS
- Slide 2
- ANTIDEPRESSANT PHARMACODYNAMICS Various classes of
antidepressants differ in their mechanism of action A thorough
understanding of this can help us choose a antidepressant in a
particular clinical situation on the basis of its efficacy and side
effect profile. The best way to understand the mechanism of action
of a drug is to know the effects of the receptors on which the drug
acts.
- Slide 3
- OVERVIEW Receptors and their actions Antidepressant
classification MOA & Important points of individual drugs Drugs
in the pipeline Review
- Slide 4
- All monoaminergic systems share common pattern of anatomical
features and metabolism.
- Slide 5
- REUPTAKE TRANSPORTERS Plasma membrane transport protein and
involves cotransport Transporter molecules for serotonin (SERT),
dopamine (DAT), and norepinephrine (NET) have been well
characterized Function: 1. Limiting the extent and duration of
activation of monoaminergic receptors. 2. Primary mechanism for
replenishing terminal monoamine neurotransmitter stores.
Interaction between significant life stressors and specific variant
alleles in predisposing individuals to affective disorders.
- Slide 6
- TERMINATION OF ACTION Action of serotonin is terminated by SERT
Reuptake Degradation of serotonin is mediated by monoamine oxidase
type A (MAO-A) MAO-A is located in mitochondrial membranes and is
nonspecific Levels of 5-HIAA are often measured as a correlate of
serotonergic system activity
- Slide 7
- Serotonin Receptors
- Slide 8
- Presynaptic 1A/1B/1D Postsynaptic
- Slide 9
- Presynaptic Receptors on Serotonergic Neurons Autoreceptors
Presynaptic Receptors Heteroreceptors - 2 5HT 1A - Somatodendritic
AR Slows Neuronal Impulse Presynpaptic AutoReceptors 5HT 1B/1D
Terminal AR Blockade of 5HT Release
- Slide 10
- Actions of Serotonin Circadian rhythm 5HT7 Mood SERT/1A 2A/2C/7
Sleep 2A/7 Appetite 2C Sex 2A/2C Pain 1B/1D BDNF 5HT6 Gut - 4
Emesis - 3 Psychosis - 2A Cognition 1A/1C Other NT Reg 2A/2C
- Slide 11
- Monoamine and Neurotrophic hypothesis of Depression Decreased
Synaptic Monoamine concentration Altered Neuroplasticity and
cellular resilience
- Slide 12
- Stress, HPA axis and BDNF
- Slide 13
- BDNF and 5-HT Signalling
- Slide 14
- ANTIDEPRESSANT CLASSIFICATION SSRI Fluoxetine, Sertraline,
Paroxetine, Fluvoxamine, Escitalopram, Citalopram SNRI Duloxetine,
Venlafaxine, Desvenlafaxine, Milnacipran, Sibutramine NDRI
Bupropion 5HT 1A Partial Agonist - Buspirone NARI - Reboxetine
NaSSA Mirtazapine SARI Trazadone, Nefazadone MaSSA -
Agomelatine
- Slide 15
- ANTIDEPRESSANT CLASSIFICATION Cyclic Antidepressants
A.Tricyclic Tertiary Amines Imipramine, Amitriptyline,
Clomipramine, Dotheipin B.Tricyclic Secondary Amines Nortriytyline,
Desipramine C.Tetracyclic Antidepressants Mianserin, Maprotiline,
Amoxapine D.Bicyclic Antidepressant Viloxazine MAOI Reversible
Selective MAOI MAOI A (RIMAs) Moclobemide MAOI B Selegiline
- Slide 16
- Receptor Profile of SSRI Serotonin Reduces Negative affect No
effect on/induces reduced positive affect Apathetic Recovery Same
Therapeutic mechanism Different Efficacy and Tolerability Due to
Secondary Pharmacological action
- Slide 17
- Why do antidepressants take time to act?
- Slide 18
- Role of 5- HT & Antidepressant in Depression Acute increase
in Synaptic 5-HT Side effects Downregulation of receptors well
before clinical resolution Tolerance to side effects Onset of
action Normalisation of CREB,BDNF And altered brain morphology
Correlates with clinical resolution of depression
- Slide 19
- Fluoxetine 5HT2C Antagonism (NDDI) Activation symptoms Anorexia
Antibulimia action at high doses Boosts antidepressant action of
Olanzapine in BPD.
- Slide 20
- Sertraline Paroxetine DOP Energy, motivation and Concentration
Sigma Anxiolytic and useful in psychotic depression For patients
with anxiety because of calming and sedating property (M 1
Antagonism) NRI - Additive antidepressant Inhibit NOS Sexual
dysfunction Notorious withdrawal reaction Cholinergic rebound
- Slide 21
- Fluvoxamine Escitalopram Sigma Agonist Anxiety and Psychotic
depression (more than sertraline) For OCD and Anxiety S Enantiomer
Robust increase in 5 HT. Most Selective and best tolerated SSRI.
Least CYP interactions.
- Slide 22
- SNRI Depression with reduced positive affect Chronic painful
physical Symptoms with depression Vasomotor symptoms of menopause
Neuropathic pain of diabetes Cognitive symptoms Fibromyalgia Two
and a half actions Dopamine in PFC. Wider Clinical spectrum +ve
& -ve affect. S.E. Activation, Agitation, HT, Tachycardia
Pseudo anticholinergic syndrome. Venlafaxamine - 5HT: NE 5 : 1
Nausea, HT,withdrawal Desvenlafaxamine Greater &predictable NE
action Duloxetine - 5HT:NE 9 : 1 less S.E than Venlafaxamine
Milnacipran NE:5HT 3 : 1
- Slide 23
- NaSSA - Mirtazapine
- Slide 24
- Mirtazapine Potent(multiple mech) Anxiolytic ( 5HT2A/2C antag,
5HT1A agonist) Sedating(5HT2A and H 1 Antagonism) No Sexual
dysfunction Weight gain ( 5HT2c and H1 antag)
- Slide 25
- Serotonin antagonist( 2A/2C )/ reuptake( SERT ) inhibitor(SARI)
Low dose - Antagonist at 5HT2A/H1/ 1 As Hypnotic; Augment ;
Increase remission High Dose SERT/5HT2C inhibition
- Slide 26
- NDRI - BUPROPION Devoid of prominent Serotonin Enhancing Action
No Sexual side effects Monotherapy Augmentation of another
antidepressant Improves positive affect Energy & Drive In
Smoking Cessation Less Switch Rate Seizures to be looked out
for
- Slide 27
- NARI - REBOXETINE Preferred in: Depression Fatigue Apathy
Psychomotor retardation Attention deficit and impaired
concentration Disorders (not limited to depression) characterized
by cognitive slowing, especially, deficiencies in working memory
and in the speed of information processing Side Effects: Unwanted
Adrenergic Excess Pseudoanticholinergic Syndrome
- Slide 28
- BUSPIRONE 5HT-1A Partial Agonist More pronounced presynaptic
agonistic action, Decreases serotonin release and thus anti-
anxiety effect Postsynaptic 5HT-1A agonism is responsible for
antidepressant effect Advantages : No sedation, sexual dysfunction,
weight gain, sleep disturbances,cognitive or psychomotor impairment
Disadvantages: Delayed onset of Action
- Slide 29
- NOVEL MELATONIN LINKED MECHANISM
- Slide 30
- Receptor profile of TCAs 1 Antagonism Orthostatic hypotension
and dizziness H1 Antagonism - Sedation and weight gain M1
antagonism Anticholinergic side effects M3 antagonism Decreases
insulin action Voltage gated ion channels Heart Cardiac arrythmias
and arrest CNS - Seizures and coma ???DIRTY DRUG
- Slide 31
- PROFILE OF CYCLIC ANTIDEPRESSANTS Prominent NE reuptake
inhibitor: Nortriptyline Desipramine Prominent 5HT reuptake
inhibitor: Clomipramine Mixed NE & 5HT reuptake inhibitor:
Amitriptyline Imipramine
- Slide 32
- MAOIs Irreversible Phenelzine, Isocarboxazid &
Tranylcypromine Reversible MAOI B Oral and transdermal Selegiline
Reversible MAOI A - Moclobemide Life threatening Hypertensive
crisis Caution when used in combination of other drugs Adequate
wash out period
- Slide 33
- VORTIOXETINE On September 30, 2013, it was approved by the U.S.
FDA for the treatment of major depressive disorder (MDD) in adults.
[2] Vortioxetine was also investigated as a treatment for
generalized anxiety disorder (GADFDAmajor depressive disorder
[2]generalized anxiety disorder Vortioxetine is a so-called
"serotonin modulator and stimulator It has been shown to possess
the following pharmacological actions Serotonin transporter (SERT)
blocker (i.e. serotonin reuptake inhibitor (SRI)) Serotonin
transporterserotonin reuptake inhibitor Norepinephrine transporter
(NET) blocker Norepinephrine transporter 5-HT 1A receptor
high-efficacy partial agonist/near-full agonist 5-HT 1A
receptorpartial agonist/near-full agonist 5-HT 1B receptor 5-HT 1B
receptor 5-HT 1D receptor antagonist 5-HT 1D receptorantagonist
5-HT 3A receptor antagonist 5-HT 3A receptor 5-HT 7 receptor
antagonist 5-HT 7 receptor Vortioxetine also has affinity for the 1
-adrenergic receptor though any actions at this site are unlikely
to contribute to its therapeutic effects and likely only to
contribute to side effectsaffinity 1 -adrenergic receptor
- Slide 34
- Triple reuptake inhibitors (TRIs) or serotonin-
norepinephrine-dopamine-reuptake inhibitors (SNDRIs):
- Slide 35
- HPA AXIS RELATED TREATMENT
- Slide 36
- NEUROKININS Ligand for NK1 receptor is Substance P. Aprepitant
(NK1 antagonist) in Phase III for depression NOVEL NEUROPEPTIDE
LINKED MECHANISM
- Slide 37
- REVIEW.. NDRI? NaSSA? Buspirone MOA? Agomelatine MOA? SSRI with
prominent sigma receptor action? TCA have cardiac side effects
because of..? SNRI with highest NE:5HT ratio? RIMA.? SARI? NARI?
Antidepressant for patients with sexual dysfunction..?
Antidepressant with highest weight gain potential?
- Slide 38